+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastroesophageal Reflux Disease Market - Growth, Trends, and Forecast (2020 - 2025)

  • PDF Icon


  • 113 Pages
  • August 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896032
UP TO OFF until Dec 31st 2023
The major factors for the growth of the gastroesophageal reflux disease market includes the rising prevalence of gastroesophageal reflux diseases and changing lifestyle, and increasing awareness about GERD.

According to the World Health Organization, in 2017, globally there are more than USD 10 billion that was found to be spent every year on antacids. As per the World Gastroenterology Organization, the prevalence rate of GERD is growing rapidly across the world. It was valued at approximately 2.5%-6.6% in South East Asia and almost 13.8%-25.8% in North America. In geriatric population, acidic complications are recurrent, which provides a unique challenge, for both, the primary care providers and gastroenterologists. Thus, rising cases of GERD the market is expected to witness high demand.

In addition, the growing number of companies for the treatment of acid reflux disorders is majorly attributable for the increase in the market.

Key Market Trends

Proton Pump Inhibitors Segment is Expected to hold the Large Market Share over the Forecast Period

Proton pump inhibitors accounted for the second largest segment as they are the most commonly prescribed medication for the treatment of acid reflux. The Proton Pump Inhibitors (PPI) characterize the maximum potency in inhibiting gastric acid secretion, primarily by blocking the acid pump. These inhibitors are well-known, for both, therapeutic effects and good safety profiles.
  • Heartburn and regurgitation are the most common acid reflux-related symptoms in Canadian patients, and many individuals self-diagnose and self-treat these symptoms. PPIs are the most successful short-term treatment for recurrent or severe heartburns. The OTC status of some PPI drugs is expected to augment their sales. Thus, owing to the all above mentioned factors the market is expected to witness a high growth.

North America is Expected to Hold the Largest Market Share over the Forecast Period

The United States is expected to be the largest market owing to the presence of better healthcare infrastructure and the rising prevalence of GERD. In the United States, tablet (chewable form) and liquid forms are most widely used. There is a rising prevalence of GERD across the world, although there are marked differences in the reported prevalence, ranging from 14% to 26% in North America.

However, it can be correlated with the rising prevalence of obesity, along with other dietary factors, in many countries. GERD can be associated with the impact on the quality of life and reduction in personal and work-related productivity. In the United States, major selling drugs include omeprazole, Pantoprazole Sodium, and Nexium. Thus, owing to the lifestyle change and rising cases of GERD the market is expected to grow.

On the other hand, the Asia Pacific region is also being projected to showcase the fastest growth rate over the forecast period due to the rising geriatric population.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corporation, Pfizer, Inc., Reckitt Benckiser Group PLC, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle
4.2.2 Increasing Awareness about GERD
4.3 Market Restraints
4.3.1 Patent Expiry of Blockbuster Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Diagnosis Upper Endoscopy Ambulatory Acid (pH) Probe Test Esophageal Manometry Others
5.1.2 Drug Type Proton Pump Inhibitors (PPIs) H2 Receptor Blockers Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 SRS Life Sciences
6.1.3 Johnson & Johnson
6.1.4 Medtronic Plc
6.1.5 Pfizer, Inc.
6.1.6 Reckitt Benckiser Group Plc
6.1.7 Takeda Pharmaceutical Co., Ltd.
6.1.8 Teva Pharmaceuticals Industries Limited.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline PLC
  • SRS Life Sciences
  • Johnson & Johnson
  • Medtronic Plc
  • Pfizer, Inc.
  • Reckitt Benckiser Group Plc
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceuticals Industries Limited.